Award Number: DAMD17-02-1-0620

TITLE: Randomized Double Blind, Placebo Controlled Trial of Neuroprotective Effects of Epoetin alfa (Procrit®) in Patients Receiving Adjuvant Chemotherapy for Breast Cancer

PRINCIPAL INVESTIGATOR: Jame Abraham, M.D.
Marc Haut, Ph.D.
Naresh Gupta, M.D.
Edward Crowell, M.D.
Eddie Reed, M.D.

CONTRACTING ORGANIZATION: West Virginia University
Morgantown, West Virginia 26506

REPORT DATE: July 2003

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20031216 058
**REPORT DOCUMENTATION PAGE**

1. **AGENCY USE ONLY**
   (Leave blank)

2. **REPORT DATE**
   July 2003

3. **REPORT TYPE AND DATES COVERED**
   Annual Summary (1 July 2002 - 30 Jun 2003)

4. **TITLE AND SUBTITLE**
   Randomized Double Blind, Placebo Controlled Trial of Neuroprotective Effects of Epoetin alfa (Procrit®) in Patients Receiving Adjuvant Chemotherapy for Breast Cancer

5. **FUNDING NUMBERS**
   DAMD17-02-1-0620

6. **AUTHOR(S)**
   Jame Abraham, M.D., Marc Haut, Ph.D.
   Naresh Gupta, M.D., Edward Crowell, M.D.
   Eddie Reed, M.D.

7. **PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**
   West Virginia University
   Morgantown, West Virginia 26506

   E-Mail: jabraham@hsc.wvu.edu

8. **PERFORMING ORGANIZATION REPORT NUMBER**

9. **SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**
   U.S. Army Medical Research and Materiel Command
   Fort Detrick, Maryland 21702-5012

10. **SPONSORING / MONITORING AGENCY REPORT NUMBER**

11. **SUPPLEMENTARY NOTES**

12a. **DISTRIBUTION / AVAILABILITY STATEMENT**
    Approved for Public Release; Distribution Unlimited

12b. **DISTRIBUTION CODE**

13. **ABSTRACT (Maximum 200 Words)**

   Cognitive deficits (e.g. problems with memory and concentration) are common during and after adjuvant breast cancer chemotherapy, but the pathophysiology of these phenomena is unknown. Cognitive impairment can, certainly, limit a patient's quality of life. The treatment of the cognitive dysfunction has not been investigated.

   (tO2) water activation using Positron Emission Tomography (PET) scan yields patterns of blood flow to brain regions used in specific cognitive skills. Studies with erythropoietin (EPO) on rat and mouse brains suggest that it protects the brain from ischemia, concussive brain injury, and toxin exposure and enhances cognitive function. We hypothesize that (tO2) water PET scan along with neuropsychological tests can evaluate the effectiveness of EPO as a treatment for cognitive dysfunction and identify the pathophysiology of cognitive dysfunction in patients receiving.

   Patients with early stage breast cancer who are candidates for adjuvant chemotherapy will undergo (tO2) water PET scans at baseline to measure the differences in regional blood flow of the brain during working memory. Specific neuropsychological tests will be done to study the attention, speeded processing, memory, and executive functions outside of the scanner. When the patients start treatment with AC they will be randomized into two groups. One group will receive weekly injections with EPO and the other group will receive placebo. PET scans and neuropsychological studies will be repeated in these two groups at the end of 4 cycles of AC.

   The trial opened to accrual in April 2003 and there are currently two patients enrolled.

14. **SUBJECT TERMS**
   No subject terms provided

15. **NUMBER OF PAGES**
   6

16. **PRICE CODE**
   Unlimited

17. **SECURITY CLASSIFICATION OF REPORT**
   Unclassified

18. **SECURITY CLASSIFICATION OF THIS PAGE**
   Unclassified

19. **SECURITY CLASSIFICATION OF ABSTRACT**
   Unclassified

20. **LIMITATION OF ABSTRACT**

**NSN 7540-01-280-5500**

**Standard Form 298 (Rev. 2-89)**

Prescribed by ANSI Std. Z38-18

298-102
Table of Contents

Cover...........................................................................................................................................Page 1
SF 298........................................................................................................................................Page 2
Introduction................................................................................................................................Page 4
Body..............................................................................................................................................Page 5
Key Research Accomplishments...............................................................................................Page 5
Reportable Outcomes..................................................................................................................Pages 5-6
Conclusions.................................................................................................................................Page 6
Annual Summary Report
Breast Cancer Research Program

Grant/Contract/MIPR No.: DAMD17-02-1-0620

Principal Investigator: Jame Abraham, MD

Institution: West Virginia University
Morgantown, West Virginia

Report Title: Randomized Double Blind, Placebo Controlled Trial of Neuroprotective Effects of Epoetin alfa (Procrit®) in Patients Receiving Adjuvant Chemotherapy for Breast Cancer

Report Type: Annual Summary Report

Award Mechanism: Idea and Career Development Award

Date of Report: July 2003

Reporting Period: July 1st 2002 to June 30th 2003

Introduction:
Adjuvant treatment with doxorubicin and cyclophosphamide (AC) clearly prolongs the overall survival in women with breast cancer. In U.S.A only, over 100,000 women will receive adjuvant chemotherapy for breast cancer every year. Cognitive deficits (e.g. problems with memory and concentration) are common during and after adjuvant breast cancer chemotherapy, but the pathophysiology of these phenomena is unknown. More importantly, treatment of the cognitive dysfunction, which can limit the quality of life of survivors, has not been investigated.

We hypothesize that \(^{15}\text{O}\) water PET scan along with neuropsychological tests can evaluate the effectiveness of EPO as a treatment for cognitive dysfunction and identify the pathophysiology of cognitive dysfunction in patients receiving.

The specific aims of the study are to: examine the efficacy of EPO as a treatment of cognitive impairment associated with adjuvant chemotherapy for breast cancer and to examine the neural changes associated with cognitive dysfunction in patients receiving adjuvant chemotherapy for breast cancer using \(^{15}\text{O}\) water PET scans.

The clinical trial has started accruing patients in April 2003.
Body:

Task 1. Study the baseline function

- Two patients with early stage breast cancer receiving adjuvant chemotherapy have been enrolled into the study.
- Baseline cognitive function assessment, with neuropsychological measures have been completed by both patients.
- The baseline study of regional blood flow of the brain using $^{15}$O water Positron Emission Tomography (PET) during working memory has been completed by both patients.

Task 2. To study the cognitive function after 4 cycles of chemotherapy with or without erythropoietin (EPO)

- 2 patients have been randomized to the study
- One patient has completed the treatment with AC and study drug per protocol and is scheduled for the PET scans and neuropsychological measures 7/9/03.
- The second patient is currently on treatment with AC and study drug per protocol.

Task 3. Analysis of the data and wiring of the final report

- All data is maintained in a cumulative database. Task 3 will be completed after the patient accrual goal is attained.

Key Research Accomplishments:

- West Virginia University received initial IRB approval of the aforementioned project on February 5, 2002.
- The Department of Defense requested many changes to the protocol and the consent form at that time; it was resubmitted to the IRB as an amendment on August 20, 2002. Due to the nature and the quantity of changes requested by the sponsor, the IRB required the protocol to be resubmitted to the full board as a new protocol. Hence, the protocol was prepared and submitted to the IRB on September 20, 2002 and approved on October 21, 2002.
- The trial was again amended to remove Ortho Biotech as a sponsor, in addition, to other minor changes. The amended protocol and consent form was submitted to the IRB on December 9, 2002 and approved on December 31, 2002.
- The study became open to enrollment in April 2003.
- All patients seen in the comprehensive breast cancer program are screened for eligibility; the first patient was screened on April 14, 2003. The first patient was enrolled into the study on April 28, 2003 and the second patient was enrolled on May 29, 2003.
- The patients on study are treated and followed per study criteria.
- There have been no reports of serious adverse events.

Reportable Outcomes:

Research article

*Presentation*

**Conclusions:**
The study is in the earliest phase. Accrual was initiated in April 2003. The data will be analyzed when the study accrual is completed.